menu
    • menu
    [{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ Nutrasource"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Sleep","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"CLA-Fortified Milk","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Hepaxa","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Omega-3 Concentrate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Palm Oil Enriched With Plant Sterols","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pronova Pure","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pronova Pure Triglycerides","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Pronovapure","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"Joe Chan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Immunology","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Joe Chan","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ Joe Chan"}]

    Find Clinical Drug Pipeline Developments & Deals by BASF

    Menu

    BASF

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palm Oil Enriched With Plant Sterols

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Institut Pertanian Bogor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plant Sterol-Enriched Palm Oil to Improve Lipid Profile and Inflammation in Hyperlipidemic Individuals

                            Details : Palm Oil Enriched With Plant Sterols is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperlipidemias.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Palm Oil Enriched With Plant Sterols

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Institut Pertanian Bogor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLA-Fortified Milk

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Recipient : Indonesia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Conjugated Linoleic Acid on Body Weight and Body Fat Mass for 12 Weeks

                            Details : CLA-Fortified Milk is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 28, 2020

                            Lead Product(s) : CLA-Fortified Milk

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Recipient : Indonesia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepaxa

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hepaxa Management of Non-alcoholic Fatty Liver Disease

                            Details : Hepaxa is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 11, 2019

                            Lead Product(s) : Hepaxa

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Memory Consolidation in Healthy Adults

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 19, 2018

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Sleep

                            Study Phase : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Sleep Efficiency in Healthy Adults

                            Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2018

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Sleep

                            Highest Development Status : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults

                            Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2017

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linoleic Acid

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CLA and Vitamin D on Protein Turnover

                            Details : Linoleic Acid is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            April 14, 2017

                            Lead Product(s) : Linoleic Acid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Joe Chan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

                            Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Transplantation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2017

                            Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Joe Chan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

                            Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 05, 2016

                            Lead Product(s) : Omega-3

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            BASF

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pronovapure

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood

                            Details : Pronovapure is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 05, 2016

                            Lead Product(s) : Pronovapure

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth